Resveratrol has been extensively studied for its multifaceted health benefits. Nonetheless, the pharmacological mechanisms of resveratrol for heart failure remain elusive, especially the cardioprotective effects. To address this knowledge gap, we performed high-throughput drug screening using zebrafish and discovered that resveratrol significantly alleviated heart failure, including rescuing abnormalities in heart rate, blood flow, cardiac output, and nppb overexpression. Mechanically, calcium optical mapping revealed that resveratrol diminished the prolongation of calcium duration at 90 % repolarization (CaD90). Membrane potential assay demonstrated that resveratrol alleviated mitochondrial damage, subsequently relieved the excessive accumulation of reactive oxygen species (ROS). Tunel staining further showed that resveratrol inhibited cardiomyocyte apoptosis both in zebrafish and human AC16 cell. Given the close relationship between the Forkhead Box O (foxo) family and oxidative stress and apoptosis, we used qPCR and noted that resveratrol could regulate the heart failure-induced expressions of foxo1b and foxo3a to normal levels. Furthermore, we conducted in situ hybridization to confirm the effective down-regulation patterns of foxo3a after resveratrol treatment. To investigate whether resveratrol's effects are mediated via foxo3a, we used gardenoside to inhibit foxo3a expression, noting that resveratrol's cardioprotective effects were reduced with foxo3a inhibition. Overall, our study underscores the molecular mechanisms by which resveratrol confers cardioprotection and provides a reference for heart failure therapeutic approaches.
Background: Programmed cell death (PCD) has recently been implicated in modulating the removal of neutrophils recruited in acute myocardial infarction (AMI). Nonetheless, the clinical significance and biological mechanism of neutrophil-related PCD remain unexplored. Methods: We employed an integrative machine learning-based computational framework to generate a predictive neutrophil-derived PCD signature (NPCDS) within five independent microarray cohorts from the peripheral blood of AMI patients. Non-negative matrix factorization was leveraged to develop an NPCDS-based AMI subtype. To elucidate the biological mechanism underlying NPCDS, we implemented single-cell transcriptomics on Cd45+ cells isolated from the murine heart of experimental AMI. We finally conducted a Mendelian randomization (MR) study and molecular docking to investigate the therapeutic value of NPCDS on AMI. Results: We reported the robust and superior performance of NPCDS in AMI prediction, which contributed to an optimal combination of random forest and stepwise regression fitted on nine neutrophil-related PCD genes (MDM2, PTK2B, MYH9, IVNS1ABP, MAPK14, GNS, MYD88, TLR2, CFLAR). Two divergent NPCDS-based subtypes of AMI were revealed, in which subtype 1 was characterized as inflammation-activated with more vibrant neutrophil activities, whereas subtype 2 demonstrated the opposite. Mechanically, we unveiled the expression dynamics of NPCDS to regulate neutrophil transformation from a pro-inflammatory phase to an anti-inflammatory phase in AMI. We uncovered a significant causal association between genetic predisposition towards MDM2 expression and the risk of AMI. We also found that lidoflazine, isotetrandrine, and cepharanthine could stably target MDM2. Conclusion: Altogether, NPCDS offers significant implications for prediction, stratification, and therapeutic management for AMI.
27 January 2023 in Journal of Healthcare Engineering
Recently, PTP1B was identified as a novel immune checkpoint whose removal can unleash T cell responses. However, research on the influence of PTP1B as an immune regulator on liver cancer is limited. This study aimed to investigate the immunological correlation and function of PTP1B in liver cancer. The expression profiles and corresponding clinical information of liver cancer patients were obtained from the TCGA and ICGC databases. GSE146115 and GSE98638 retrieved from the GEO database were used for the single‐cell RNA‐seq analysis. The mRNA expression of PTP1B (PTPN1) was increased in patients with most malignancies (all p < 0.05), including liver cancer (p < 0.001). Furthermore, up‐regulated PTPN1 was connected to advanced tumor stage (p < 0.05) and worse prognosis (p < 0.01) in liver cancer. Through Cox regression analysis, PTPN1 was considered as an independent prognosis factor of overall survival (p < 0.05) and acted as a high‐risk factor (hazard ratio > 1). Gene function and pathway analysis suggested PTPN1 was involved in T cell‐related immune responses. Moreover, a close relationship was also found between PTPN1 expression and immune checkpoints as well as immune cells, especially with T cell‐related checkpoints (all p < 0.001) and T cells (all p < 0.001). Single‐cell RNA‐seq analysis further illustrated that the enrichment of PTPN1 in the T cell population may be linked to its exhaustion in the liver cancer microenvironment. Overall, PTPN1 (PTP1B) closely related to T cell may function as an immunotherapy target for liver cancer.
24 December 2025 in QJM: An International Journal of Medicine
Long-live species have evolved divergent mechanisms of cancer resistance, offering novel inspiration for human oncology. Particularly noteworthy are recent studies on the bowhead whale and naked mole-rat, highlighting the translational potential of enhanced DNA repair mechanisms for humans. Inspired by this, we propose potential strategies for advancing cancer prevention and immunotherapy.
Migrasomes, recently discovered extracellular organelles, are implicated in cancer progression and immune regulation. Nevertheless, their roles in cancer immunotherapy resistance remain poorly understood. To address this gap, we integrated cutting-edge computational engines to identify migrasome-associated targets modulating cancer immunotherapy. Using the Cancer Immunology Data Engine (CIDE) covering 5,957 patients across 17 tumor types, TSPAN6 was identified as significantly associated with adverse immunotherapy outcomes. Pan-cancer validation across the TCGA, ICGC, and CPTAC cohorts confirmed that elevated TSPAN6 expression significantly correlates with adverse prognosis. Using the pan-cancer atlas of over 4.4 million cells, we revealed the specific expression of TSPAN6 in malignant cells. Additionally, TSPAN6-high malignant cells significantly up-regulate immune checkpoint genes including CD274, NECTIN2, and LGALS9, thereby enhancing immunosuppressive interactions with exhausted T cells. Genetic ablation of TSPAN6 in co-culture models enhanced anti-tumor immunity, functionally validating this mechanism. Spatial transcriptomics further demonstrated TSPAN6 enrichment in tumor cores and its significant downregulation in immunotherapy responders compared to non-responders. In our validation cohorts, paired serum samples from 44 cancer patients showed significantly decreased TSPAN6 levels following immunotherapy. To overcome TSPAN6-mediated resistance, we computationally screened 1,615 FDA-approved compounds for inhibiting TSPAN6. Among these drugs, mitoxantrone demonstrated high-affinity binding to TSPAN6 through hydrogen bonding and hydrophobic interactions with TSPAN6. Collectively, our findings establish TSPAN6 as a migrasome-related regulator driving adverse immunotherapy outcomes and responses. Targeting TSPAN6, potentially with mitoxantrone, presents a potential strategy to enhance immunotherapy efficacy.
8 October 2025 in Biochemical and Biophysical Research Communications